An Observational Study of Herceptin SC Safety in Breast Cancer
NCT02305628 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2020-11-16
Summary
This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-26
- Primary Completion
- 2020-01-31
- Completion
- 2020-01-31
Countries
- South Korea
Study Locations
More Related Trials
-
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
NCT01940497 ·Status: COMPLETED ·Phase: PHASE3
-
To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)
NCT06687928 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
NCT02658461 ·Status: COMPLETED
-
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
NCT04276337 ·Status: UNKNOWN
-
A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
NCT01964391 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
NCT01548677 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
NCT01301729 ·Status: COMPLETED ·Phase: PHASE4
-
Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
NCT06837792 ·Status: RECRUITING ·Phase: PHASE2
-
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
NCT01401166 ·Status: COMPLETED ·Phase: PHASE2
-
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
NCT00045032 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)
NCT01926886 ·Status: COMPLETED ·Phase: PHASE3
-
H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer
NCT01991340 ·Status: COMPLETED
-
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
NCT01152606 ·Status: COMPLETED
-
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
NCT01928615 ·Status: TERMINATED ·Phase: PHASE2
-
Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer
NCT02424682 ·Status: COMPLETED
-
A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
NCT00800436 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab
NCT00532857 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
NCT06504719 ·Status: COMPLETED
-
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
NCT00433407 ·Status: COMPLETED ·Phase: NA
-
Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
NCT07047755 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
NCT02586025 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
NCT00545688 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
NCT02194166 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
NCT03556358 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
NCT02748213 ·Status: COMPLETED ·Phase: PHASE2